This report analyzes the US Market for Diabetic Retinopathy in US$ Million. Annual estimates and forecasts are provided for the period 2011 through 2015. The report profiles 40 companies including many key and niche players such as Allergan, Inc., AstraZeneca PLC., Eyetech, Inc., Fovea Pharmaceuticals SA, Genentech, Inc., Gene Signal, Isis Pharmaceuticals, Inc., Lpath, Inc., MacuSight, Inc., OM Pharma S.A, OPKO Health, Inc., Oxford BioMedica Plc., pSivida Corp., Quark Pharmaceuticals, Inc., Sanwa Kagaku Kenkyusho Co., Ltd., Sirnaomics, Inc., Suzuken Co., Ltd., and Vitreoretinal Technologies, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

I.Introduction, Methodology & Product Definitions
- Study Reliability and Reporting Limitations
- Disclaimers
- Data Interpretation & Reporting Level
- Quantitative Techniques & Analytics
- Product Definitions and Scope of Study
II. a US Market Report
- 1.Market Outlook
- Incidence and Prevalence of Diabetic Retinopathy Continue to Rise
- Table 1: Diabetic Retinopathy Patient Prevalence in the US by Diabetes Type: 2006-2015 (In Thousand Patients) (Includes Corresponding Graph/Chart)
- Table 2: Diabetic Retinopathy Patient Prevalence in the US by Age Group: 2006-2012 (Includes Corresponding Graph/Chart)
- Table 3: Diabetic Retinopathy Prevalence in Type-1 Diabetic Patients in the US by Age Group: 2006-2012 (Includes Corresponding Graph/Chart)
- Prevalence of Diabetes on the Rise
- Huge Unmet Needs Fuel Demand for Pharmacological Drugs
- Market Awaits First Approved Drug; Off-Label Use Continues
- Diabetic Retinopathy Drug Market to Post Dramatic Growth
- Insulin – a Potential Therapy for Diabetic Retinopathy
- Additional Trials Delay Arxxant's Launch
- Lucentis Shows Promise in Diabetic Retinopathy Treatment
- Avastin and Lucentis to Compete on Price
- Pycnogenol Continues to Appeal to Researchers
- Robo4 Protein – a Potential Therapeutic for Diabetic Retinopathy
- Bevacizumab Bodes Potential As an Adjunct to Surgery Pdr Treatment
- 2.Diabetic Retinopathy Drug Class – an Overview
- Drug Classes in Diabetic Retinopathy
- Vegf Inhibitors
- Pegaptanib
- Bevacizumab
- Ranibizumab
- Pkc Inhibitors
- Corticosteroids
- Aldose Reductase - Age Inhibitors
- Somatostatin Analog
- Other Pharmacological Therapeutic Agents
- 3.Pipeline Overview
- Select Pipeline Drugs in Diabetic Retinopathy Market
- An Overview of Select Pipeline Drugs
- Arxxant (Eli Lilly)
- Iluvien® (Psivida Corp.)
- Atacand (Astrazeneca)
- Lucentis (Genentech and Novartis)
- Avastin (Genentech/Roche)
- Vitreosolve® (Vitreo Retinal Technologies)
- Posurdex (Allergan)
- Macugen (Eyetech)
- Cand5 (Opko Health, Inc.)
- Pf-4523655 (Quark Pharmaceuticals/Pfizer)
- Intravitreal Triamcinolone Acetonide (Allergan)
- Peribulbar Triamcinolone Acetonide (Bristol Myers)
- Microplasmin (Thrombogenics N.V.)
- Aflibercept (Regeneron/Bayer)
- Sirolimus (Macusight/Santen)
- Ico-007 (Ico Therapeutics)
- Other Drugs With Potential Benefits in Dr Treatment
- 4.Disease Overview
- Diabetes
- Quick Facts on Diabetes
- Diabetic Retinopathy
- Leading Cause of Blindness in Diabetic Population
- Pathogenesis of Diabetic Retinopathy
- Clinical Features
- Proliferative and Non-Proliferative Diabetic Retinopathy
- Diabetic Macular Edema
- Risk Factors for the Condition
- Symptoms
- Prevention of Diabetic Retinopathy
- Detection of Proliferative Retinopathy and Macular Edema
- Visual Acuity Test
- Fundus Fluorescein Angiography
- Ophthalmoscopy
- Optical Coherence Tomography
- Non-Mydriatic Fundus Photography
- Dynamics of Evaluating Technologies
- Frequency of Examinations
- Treatment for Diabetic Retinopathy
- Laser Surgery
- Scatter Laser Treatment/ Panretinal Photocoagulation
- Focal Laser Treatment/ Photocoagulation
- Vitrectomy
- Kenalog/ Triamcinolone Actinomide
- 5.Recent Industry Activity
- Sanofi-Aventis to Take Over Fovea Pharmaceuticals
- New Injectable Steroid In-Line From Wakamoto Pharmaceutical
- Sirion Therapeutics and Advanced Vision Research Signs Agreement
- Activesite Develops Protease Inhibitor for Treating Diabetic Retinopathy
- Pipex Acquires Global License for Additional Usage of Oral Flupirtine
- Macusight and Santen Ink License Agreement
- Optimedica Enters Into Distribution Agreement With Topcon Medical
- Lpath Submits Ind for Isonep™
- Iris Pharma Merges With Clirophtha
- Isis Receives Milestone Payment for Initiating Trials of Ico-007
- Eli Lilly Withdraws Marketing Authorization Application for Arxxant in Europe
- Thrombogenics Begins Phase IIb Trial of Microplasmin in the Us
- 6.Focus on Select Global Participants
- Allergan, Inc. (US)
- Astrazeneca Plc (Uk)
- Eyetech, Inc. (US)
- Fovea Pharmaceuticals Sa (France)
- Genentech, Inc. (US)
- Gene Signal (Switzerland)
- Isis Pharmaceuticals, Inc. (US)
- Lpath, Inc. (US)
- Macusight, Inc. (US)
- Om Pharma S.A (Switzerland)
- Opko Health, Inc. (US)
- Oxford Biomedica Plc. (Uk)
- Psivida Corp. (US)
- Quark Pharmaceuticals, Inc. (US)
- Sanwa Kagaku Kenkyusho Co., Ltd. (Japan)
- Sirnaomics, Inc. (US)
- Suzuken Co., Ltd. (Japan)
- Vitreoretinal Technologies, Inc. (US)
- 7.Us Market Forecasts
- Table 4: US Diabetic Retinopathy Drugs Market Potential: Annual Sales Forecasts in Us$ Million for Years 2011 Through 2015 (Includes Corresponding Graph/Chart)
III. Competitive Landscape
- Total Companies Profiled: 40 (Including Divisions/Subsidiaries - 43)
- Region/Countryplayers
- The United States
- Canada
- Japan
- Europe
- France
- Germany
- The United Kingdom
- Rest of Europe

Pharmaceutical Market Research

Diabetic Retinopathy

Diabetic Retinopathy

Contents

Related products